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Abstract: 
We predict vaccine efficacy with a measure of antigenic distance between influenza A(H3N2) 
and candidate vaccine viruses based on amino acid substitutions in the dominant epitopes. In 
2016-2017, our model predicts 19% efficacy compared to 20% observed.  This tool assists 
candidate vaccine selection by predicting human protection against  circulating strains.  
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Text: 
Seasonal influenza constitutes a significant disease burden worldwide, with three to five million 
cases of severe illness and an estimated annual death toll of 290,000 to 650,000; however, 
vaccination can provide protection [1].  The vaccine component against influenza A(H3N2) is 
especially important, as increased morbidity and mortality are associated with this most 
commonly predominant subtype [2].  Influenza type A viruses are primarily recognized by the 
immune system via two proteins on their surface, hemagglutinin (HA) and neuraminidase [3].  
These viruses constantly evolve to evade human antibodies, most notably by introducing amino 
acid substitutions into the HA binding sites, designated epitopes A through E in A(H3N2) 
(Supplementary Figure 1).  Some epitopes appear to play a more dominant role during infection 
than others, and the one under the greatest immune pressure in a given season will have the 
highest percentage of amino acid substitutions, computed by dividing the number of substitutions 
by the total number of amino acids in that epitope [4].  Increased antigenic distance between the 
vaccine and infecting virus leads to decreased vaccine efficacy.  Due to virus evolution, the 
World Health Organization (WHO) recommends the composition of the seasonal influenza 
vaccine twice a year based on the dominant influenza strains from the previous northern or 
southern hemisphere season [5].  Several antigenically similar candidate vaccine viruses (CVVs) 
and associated reassortants are made available.  Generally, the reassorted viruses used in 
manufacturing the vaccine are antigenically identical to their CVV prototypes in the HA region 
[6].  For the 2016-2017 northern hemisphere influenza season, WHO recommended A/Hong 
Kong/4801/2014 (H3N2)-like CVVs [5]. However, vaccine efficacy for adults aged 18-64 
against A(H3N2) influenza was only 20 ± 8% [2] (Supplementary Methods).  Rather than an 
increased antigenic distance due to virus evolution, the 2016-2017 vaccine may have diverged 
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from circulating viruses due to substitutions acquired during isolation of the CVV strains in eggs 
[7].  Passaging-related adaptations have posed an issue for A(H3N2) CVVs in particular [8,9] 
(Supplementary Table 3).  
 
We have previously derived a statistical mechanics model that captures the dynamics of human 
antibody-mediated response to viral infection following vaccination [10].  In a recent application 
of our theory, we used the evolution of the dominant HA epitope to predict vaccine efficacy, the 
ability of the vaccine to reduce the disease attack rate [4].  Here we generalize the model to 
A(H3N2) data both from the 1971-1972 to 2015-2016 influenza seasons and from highly 
consistent, laboratory-confirmed studies over the past decade.  Additionally, we expand the 
prediction to encompass average efficacy against an abundance of diverse A(H3N2) strains for a 
given season.  We apply this novel approach to quantify antigenic distance and expected efficacy 
of the egg-adapted CVVs against all strains circulating during the 2016-2017 and early 2017-
2018 seasons. 
 
Methods 
The epitope-based dependence of vaccine efficacy in our model comes from a measure of 
antigenic distance termed pepitope, where 
.  (1) 
In ferret models, the typical measure of antigenic distance d1 is the log2 difference between 
vaccine antiserum titer against itself and the vaccine antiserum titer against a strain 
representative of the dominant circulating viruses [11].  A second measure d2 is the square-root 
ratio of the product of the homologous titers to the product of the heterologous titers [12].  We 
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perform linear regression with vaccine efficacy data reported by WHO collaborating centers to 
compare the predictive power of pepitope with these ferret-based distances.  We then utilize our 
model to evaluate the primary protein structure of egg-adapted A/Hong Kong/4801/2014 CVV in 
the context of the 2016-2017 season [5] and to predict efficacy of the egg-adapted CVV for the 
newly recommended A/Singapore/INFIMH-16-0019/2016 (H3N2)-like vaccine [13].  Finally, 
we calculate the average efficacy of the CVVs against 6610 circulating A(H3N2) strains 
collected from September 2016 to November 2017, a unique capability of our pepitope measure of 
antigenic distance in comparison to other clinical studies. 
 
Results 
Our use of pepitope to correlate antigenic distance with vaccine efficacy yields a coefficient of 
determination r2 = 0.77 on both data since 1971 and data over just the past 10 years (Figure 1).  
Conventional ferret d1 has r2 = 0.42 on data since 1971 and has dropped to r2 = 0.23 on data over 
the past 10 years.  The extracted equation to predict vaccine efficacy VE is 
,    (2) 
where the standard error on the slope is  ±0.254 and the standard error on the y-intercept is  
±0.032 (Supplementary Methods).   
 
We calculate pepitope = 0.095 between the egg-adapted A/Hong Kong CVV and 
A/Colorado/15/2014, a representative clade 3C.2a strain [7], and find the dominant epitope is B, 
with amino acid substitutions T160K and L194P.  The reassorted CVVs contain some additional 
substitutions (Supplementary Figure 2), but as these substitutions are outside of the dominant 
epitope, we focus on the non-reassorted CVV for our analysis.  Using Equation 2, we predict 
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vaccine efficacy against this A/Colorado strain to be 23 ± 4% (Supplementary Table 1).  The 
hemagglutination inhibition titers from post-infection ferret antisera reported for the 2016-2017 
season [14] and our linear regressions of d1 and d2 predict vaccine efficacy to be 27 ± 5% and 28 
± 4%, respectively.  Analysis of the reference A/Hong Kong strain, which was the clinical 
specimen collected from humans and expected to dominate in the population, reveals that this 
strain did not exhibit the epitope B substitutions.  We predict it would have had a high 47 ± 3% 
efficacy against A/Colorado. 
 
When comparing the CVVs to all circulating strains during the 2016-2017 and early 2017-2018 
seasons, we considered both pepitope (Equation 1) and the Hamming distance, which is the number 
of differing amino acids between each pair of strains in HA subunit 1 divided by the total 328 
amino acids of the subunit.  While the Hamming distance between the reference A/Hong Kong 
specimen and the consensus sequence of the circulating strains is 0.006, that of the egg-adapted 
CVV’s is 0.015 (Supplementary Figure 2).  For the egg-adapted A/Hong Kong CVV, the average 
pepitope is 0.111 due to substitutions in dominant epitope B, with an average predicted vaccine 
efficacy of 19 ± 4%.  The reference A/Singapore/INFIMH-16-0019/2016 specimen has a 
Hamming distance of 0.003 to the consensus strain, smaller than the reference A/Hong Kong 
specimen has, and that of its egg-adapted CVV is 0.012.  We calculate that the egg-passaged 
A/Singapore CVV has an average pepitope of 0.118, leading to a predicted average vaccine 
efficacy of 18 ± 4%. 
  
Discussion 
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We quantify influenza virus evolution and predict the ability of the CVV to reduce the disease 
attack rate using our pepitope measure of antigenic distance.  While other factors influence real-
world vaccine effectiveness in humans, pepitope has accounted for much of the variance in CVV 
efficacy over the past 10 and 45 years (r2 = 0.77).  The low vaccine performance against 
A(H3N2) during 2016-2017 appears to have been caused by the T160K and L194P substitutions 
that occurred in the dominant epitope B during egg-isolation of the A/Hong Kong CVV.  Indeed, 
human antisera studies showed that individuals who had received the Flublok recombinant 
influenza vaccine (containing T160 and L194) that had been passaged in insect cells produced 
more effective antisera than did those who had received the inactivated influenza vaccines 
Fluzone or Flucelvax (containing K160 and P194) [7], which were both made from CVVs 
initially isolated in eggs [9].  Arguably, HA stability did not account for the larger response 
induced by Flublok, since all three vaccines induced a similar antisera response when challenged 
by K160-containing viruses [7]. 
 
It is critical to choose a vaccine strain with the minimal antigenic distance from all circulating 
A(H3N2) strains.  While the reference A/Singapore specimen minimizes the Hamming distance, 
the reference A/Hong Kong specimen minimizes pepitope (Supplementary Figure 3).   WHO 
changed the recommended CVVs for the southern hemisphere because the egg-passaged 
A/Singapore CVV contains an N121K substitution that matches the majority of recent viruses, 
and ferret antisera were more successfully raised [13].  However, the egg-passaged A/Singapore 
CVV has two substitutions in residue B (T160K and L194P) that do not match the majority of 
circulating strains. We predict that this A/Singapore CVV will have comparable efficacy to the 
egg-passaged A/Hong Kong CVVs in humans. 
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The pepitope of a pair of strains can be calculated nearly instantaneously or averaged for one strain 
against 6000 in seconds.  By contrast, ferret models are restricted to a few analysis pairs, antisera 
production takes 3-5 weeks, and there is added difficultly due to strict biocontainment measures 
[9].  Additionally, pepitope theory suggests which sequence discrepancies are contributing most to 
a lowered vaccine efficacy.  We currently do not explicitly consider N-linked glycosylation, 
though pepitope implicitly incorporates this seeing as discrepancies in glycosylation between two 
strains are generally due to amino acid substitutions, e.g., T160K caused an observed lack of 
glycosylation site in the A/Hong Kong CVV as compared to circulating 3C.2a strains [7].  Our 
model can rapidly narrow down clinical specimens that are representative of viruses that will 
dominate the upcoming flu season.  It can then be used in cooperation with ferret models to 
confirm that the CVVs and their associated reassortants have not acquired critical antigenic 
changes before the vaccine is manufactured and administered to the human population 
worldwide. 
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Figure 1.  
Influenza A(H3N2) vaccine efficacy as a function of three measures of antigenic distance. We 
plot pepitope (red) from our model, d1 (green) and d2 (blue) from ferret serological studies [11,12], 
and the corresponding vaccine efficacy values for each influenza season.  Linear regression of 
data from each measure of antigenic distance is shown for the past 45 years (solid lines) and for 
laboratory-confirmed studies in the past 10 years (dotted lines). The coefficients of determination 
(r2) are listed in the legend.  Data for the 2016-2017 season are plotted separately (diamond 
points).  The strong and consistent r2 between pepitope and vaccine efficacy indicates that this 
model accurately predicts the data.  We determined an average efficacy of 19 ± 4% for the 2016-
2017 egg-adapted A/Hong Kong/4801/2014 vaccine, whereas 20 ± 8% was observed [2]. 
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Supplemental Methods 
Calculation of pepitope and Hamming distance from sequence data. 
All hemagglutinin (HA) sequence data were obtained from the GISAID Platform's open access EpiFlu database [1] 
(Supplementary Table 2).  We downloaded all sequences of H3N2 clinical specimens collected from humans between September 2016 
and November 2017 that had been uploaded before 18 November 2017 (totaling 6610 HA sequences).  To determine the dominant 
epitope and pepitope, we select the 328 amino acids that are part of subunit one of the HA protein (HA1) and calculate the amino acid 
discrepancies for individual epitopes, scaled by the total number of amino acids in each epitope (Equation 1; Supplementary Figure 2). 
The consensus strain is the sequence containing the most common amino acid in each position among all sequences.  The Hamming 
distance between each pair of strains is the number of amino acids discrepancies in the complete HA1 region, divided by the size of 
HA1 (328 amino acids), 
            (S1). 
 
Calculation of antigenic distance from ferret serological studies. 
We use hemagglutination inhibition assay results to obtain the vaccine antiserum titer against itself H11, the vaccine antiserum 
titer against a strain representative of the dominant circulating viruses H21, the dominant strain antiserum titer against itself H22, and 
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the dominant strain antiserum titer against the vaccine strain H12.  The equations for antigenic distances d1 [2] and d2 [3] are defined 
as, 
 and  .  (S2) 
 
Vaccine efficacy. 
We define vaccine efficacy from the rate of infection in unvaccinated individuals  and the rate of infection in 
vaccinated individuals   as 
,     (S3) 
where Nu is the total number of unvaccinated individuals, Nv is the total number of vaccinated individuals, nu is the number of 
unvaccinated individuals who tested H3N2-positive, and nv is the number of vaccinated individuals who tested H3N2-positive.  
Estimates of the standard error for these rates and vaccine efficacy are 
,  , and  . (S4) 
To minimize inevitable bias in vaccine efficacy due to individuals with a non-optimal immune system or differences in 
epidemiological study site procedures, we select only healthy adults aged 18-64 years and individuals vaccinated by inactivated 
viruses.  We use the data for our population of interest from [4].  For the combined 18-64 cohort, 322 individuals were A(H3N2) 
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positive, 143 of which had been vaccinated, meaning 179 had not been vaccinated.  Additionally, the data shows that 1208 individuals 
were A(H3N2) negative, 624 of which had been vaccinated, meaning 584 had not been vaccinated.  From these numbers, we see that 
there were 763 total unvaccinated individuals and 767 total vaccinated individuals.  It then follows that the rate of infection 
(Supplementary Equation S3) in unvaccinated individuals is 179 / 763 = 0.2346 and the rate of infection in vaccinated individuals is 
143 / 767 = 0.1864.  The A(H3N2) vaccine efficacy for this cohort is then (0.235 - 0.049) / 0.235 = 0.2053, or 20%.  We then 
calculated the standard error to be ± 8%  using Supplementary Equation S4. 
 The standard error for the vaccine efficacy predicted by each measure of antigenic distance through linear regression is 
,    (S5) 
where σm is the standard error on the slope, σb is the standard error on the y-intercept, and x is either pepitope, d1, or d2. 
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Supplementary Figure 1 
Protein structure of HA for an H3N2 strain.  Amino acid residues in subunit one of HA are filled and color-coded for each epitope, A 
(red, 19 amino acids), B (yellow, 21 amino acids), C (green, 27 amino acids), D (blue, 41 amino acids), and E (purple, 22 amino acids) 
[5,6].  The two dominant-epitope amino acid residues differing between clade 3C.2a circulating viruses and the egg-adapted candidate 
vaccine viruses (CVVs) for A/Hong Kong/4801/2014 and A/Singapore/INFIMH-16-0019/2016 are colored darker gold and labeled.  
Figure generated with MATLAB Molecule Viewer using Protein Data Bank entry 2VIU [7]. 
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Supplementary Figure 2 
The fractional number of substitutions in each HA epitope, as determined by dividing the number of substitutions by the total number 
of amino acids in the epitope. Clinical specimen reference (Ref.) strains, A/Hong Kong/4801/2014 and A/Singapore/INFIMH-16-
0019/2016, and egg-adapted (Egg) CVVs are compared to the dominant circulating viruses, (A) A/Colorado/15/2014 and (B) 
A/Singapore/INFIMH-16-0019/2016. Discrepancies are detailed inside the bar segments, e.g., T160K means there is a T to K 
substitution in residue 160.  The pepitope is calculated according to Equation 1 from the dominant epitope, which is the epitope that has 
the largest fractional discrepancy.  The reassorted CVVs for A/Hong Kong (X263, X263A, and X263B) and for A/Singapore (IVR-
186, NIB-104, X-307, and X-307A) are also compared to (C) A/Hong Kong (Egg) and (D) A/Singapore (Egg), respectively. 
(A)  (B)  
 (C)  (D)  
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Supplementary Figure 3 
We performed dimensional reduction using multidimensional scaling of the (A) Hamming distance and (B) pepitope between all 
circulating strains to display the comparison of sequence-space minimization of the clinical specimen reference and egg-adapted CVV 
strains.  These plots contain 6339 H3N2 strains collected from September 2016 to August 2017 and 271 strains collected from 
September 2017 to November 2017.  There does not seem to be a significant shift in the H3N2 quasispecies cluster at this point in the 
2017-2018 season.  Surveillance of the rates of infection and dominant circulating strains over the remainder of this 2017-2018 
influenza season will reveal whether a new, distinct cluster is forming. 
(A)  (B)  
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Supplementary Table 1   
Summary of strains analyzed with our model.  The value of pepitope is calculated with Equation 1, predicted vaccine efficacy is 
calculated with Equation 2 and Supplementary Equation S5, and observed vaccine efficacy it is calculated with Supplementary 
Equations S3 and S4 (nu, Nu, nv, Nv are defined with Supplementary Equation S3).  Serological measures of antigenic distance (d1, d2) 
are calculated from Supplementary Equation S2. The accession numbers for the GISAID database are listed under each isolate.  
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Supplementary Table 2  
GISAID Acknowledgements.  We gratefully acknowledge the originating and submitting laboratories of the hemagglutinin (HA) 
sequences from GISAID’s EpiFluTM Database on which this research is based [1].  The list is detailed below.  All submitters of data 
may be contacted directly via the GISAID website (http://www.gisaid.org). 
Isolate ID Segment ID Segment Country Date Isolate Name Originating Laboratory Submitting Laboratory 
EPI_ISL_164719 EPI537866 HA Switzerland 2013-Dec-6 A/Switzerland/9715293/2013 
National Institute for Medical 
Research 
Centers for Disease Control and 
Prevention 
EPI_ISL_165554 EPI539576 HA Hong Kong 2014-Feb-26 A/Hong Kong/4801/2014 Government Virus Unit 
National Institute for Medical 
Research 
EPI_ISL_218060 EPI741474 HA UK 2016-Apr-22 A/Hong Kong/4801/2014 (15/192) Francis Crick Institute 
National Institute for Biological 
Standards and Control 
EPI_ISL_189810 EPI614406 HA USA 2014 A/Hong Kong/4801/2014 X-263 New York Medical College Centers for Disease Control and Prevention 
EPI_ISL_215973 EPI731467 HA UK 2016-Apr-5 
A/Hong Kong/4801/2014 X263A 
(15/188) New York Medical College 
National Institute for Biological 
Standards and Control 
EPI_ISL_215974 EPI731469 HA UK 2016-Apr-5 
A/Hong Kong/4801/2014 X263B 
(15/184) New York Medical College 
National Institute for Biological 
Standards and Control 
EPI_ISL_167408 EPI545672 HA USA 2014-Oct-4 A/Colorado/15/2014 
Colorado Department of Health 
Laboratory 
Centers for Disease Control and 
Prevention 
EPI_ISL_225834 EPI780183 HA Singapore 2016-Jun-14 
A/Singapore/INFIMH-16-
0019/2016 Ministry of Health, Singapore Ministry of Health, Singapore 
EPI_ISL_282899 EPI1086288 HA UK 2017-Oct-24 
A/Singapore/INFIMH-16-
0019/2016  (17/196) 
Victorian Infectious Diseases 
Reference Laboratory 
National Institute for Biological 
Standards and Control 
EPI_ISL_285605 EPI1104214 HA UK 2017-Nov-22 
A/Singapore/INFIMH-16-
0019/2016  IVR-186  (17/210) 
National Institute for Biological 
Standards and Control 
National Institute for Biological 
Standards and Control 
EPI_ISL_282213 EPI1082230 HA UK 2017-Oct-16 
A/Singapore/INFIMH-16-
0019/2016  NIB-104 (17/194)  
National Institute for Biological 
Standards and Control 
National Institute for Biological 
Standards and Control 
EPI_ISL_293533 EPI1151848 HA USA 2016 A/Singapore/Infimh-16-0019/2016 X-307 New York Medical College 
Centers for Disease Control and 
Prevention 
EPI_ISL_293527 EPI1151800 HA USA 2016 A/Singapore/Infimh-16-0019/2016 X-307A New York Medical College 
Centers for Disease Control and 
Prevention 
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Supplementary Table 3 
Historical occurrences of egg-adaptation issues with A(H3N2) vaccines.  Several times the WHO has chosen a clinical specimen 
reference strain for the CVVs that is well-matched to the dominant circulating virus strain during that season, but the egg-passaged 
CVV strain (or “like” strain) adapted with critical antigenic changes.  We quantify the antigenic distance between the egg-passaged 
CVV and the dominant circulating virus from each of these seasons using pepitope.  In the years listed here, pepitope between the reference 
strain and the dominant circulating strain is zero.  Accession numbers below each strain are from GISAID [1]. 
  
 
Season Candidate Vaccine Virus Reference (Clinical Specimen) 
Candidate Vaccine Virus 
(Egg passaged) Dominant Circulating Strain 
Dominant 
epitope pepitope 
Observed 
Vaccine Efficacy 
1996-97 A/Wuhan/359/1995 EPI_ISL_758 - EPI3775 
A/Nanchang/933/1995 
EPI_ISL_167267 - EPI545305 
A/Wuhan/359/1995 
EPI_ISL_758 - EPI3775 B 0.0952 
28% 
[11] 
2004-05 A/Fujian/411/2002 EPI_ISL_111384 - EPI362915 
A/Wyoming/3/2003 
EPI_ISL_3767 - EPI160210 
A/Fujian/411/2002 
EPI_ISL_111384 - EPI362915 B 0.0952 
9% 
[12] 
2011-12 A/Victoria/361/2011 EPI_ISL_167307 - EPI545346 
A/Perth/16/2009 
EPI_ISL_176456 - EPI577972 
A/Victoria/361/2011 
EPI_ISL_167307 - EPI545346 C 0.1111 
23% 
[12] 
2012-13 A/Victoria/361/2011 EPI_ISL_167307 - EPI545346 
A/Victoria/361/2011 
EPI_ISL_132936 - EPI408194 
A/Victoria/361/2011 
EPI_ISL_167307 - EPI545346 B 0.0952 
35% 
[12] 
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